Biodefence Market is predicted to reach USD 26.89 billion at a CAGR of 7.01% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Biodefence Market”.The Biodefence market is estimated to register a CAGR of 7.01% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global biodefence market— Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US).

Biodefence Market Highlights

The global biodefence market is accounted for to register a CAGR of 7.01% during the forecast period and is estimated to reach USD 26.89 billion by 2032.

The global prevalence of various agents such as ebola virus, zika virus, anthrax and others driving the biodefense market in coming years. These diseases have the potential to have a significant impact on public health, are easily transmissible from person to person, have high mortality rates, could cause widespread panic and social unrest, and call for special precautions to ensure public health preparedness. For instance, according to the Communicable Disease Threat Report from the European Centre for Disease Prevention and Control (ECDC), 15 human cases of cutaneous anthrax were connected to a cattle anthrax outbreak in Sisak-Moslavina County in July 2022 as a result of heavy rain in the region.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Biodefence Market Research Report

Segment Analysis

The global Biodefence market has been segmented based on disease type, and treatment.

On the basis of the disease type, the market is segmented into anthrax, small pox, botulism, influenza, radiation/nuclear, and others. The anthrax segment was attributed to holding the largest market share in 2023 revenue as estimated by MRFR analysis.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new collaborations and partnerships.

Regional Analysis

The global Biodefence market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe Biodefence market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Biodefence market in Asia-Pacific has been segmented into India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the world’s Biodefence market comprises of Middle East, Africa, and Latin America.

the country's compatible technical and healthcare infrastructure are expected to foster North America’s market growth. Moreover, high expenditure in research and development activities by the market players and, presence of several major players, such as Emergent BioSolutions Inc. (US) and Siga Technologies, Inc. (US) among others drive the growth of the market are expected to support market growth.

Moreover, the Europe market has been persistently growing owing to increase in the prevalence of chronic disease and the rise in research and development activities for biodefense solutions across the region.

Additionally, market factors, such as the expansion of healthcare facilities, increase in prevalence of patient population across the region are driving the Asia-Pacific region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The Middle East region is the major contributor to the market. increase in the prevalence of infectious diseases such as Covid-19, influenza, and others have driven the market growth in the Middle East & Africa.

Key Findings of the Study

• The global Biodefence market is expected to reach USD 26.89 billion by 2032, at a CAGR of 7.01% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the increase in the number of reported infections of communicable diseases and extensive outbreaks of infectious diseases such as influenza, Covid-19 and others are posing a serious health risk to consumers in the region.


• Based on disease type, the anthrax segment was attributed to holding the largest market in 2023, with an approximate market share of around 42.86%.


• Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are the key market players.